Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.52 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.43 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 6/20 | 0.42 |
| ▸ | NOS1 | P29475 | 4/20 | 0.42 |
| ▸ | NOS3 | P29474 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ARG1 | P05089 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22691090 | 1.00 | OTC (0.52) | OTCDDAH1GSRNOS2NOS1 | |
| SCHEMBL13445977 | 1.00 | OTC (0.52) | OTCDDAH1GSRNOS2NOS1 | |
| SCHEMBL20528882 | 0.95 | OTC (0.57) | OTCDDAH1GSRNOS2NOS1 | |
| SCHEMBL21611916 | 0.95 | OTC (0.48) | OTCDDAH1GSRNOS2NOS1 | |
| SCHEMBL21611915 | 0.95 | OTC (0.48) | OTCDDAH1GSRNOS2NOS1 | |
| SCHEMBL29286204 | 0.89 | OTC (0.45) | OTCDDAH1GSRNOS2NOS1 | |
| SCHEMBL29286205 | 0.89 | OTC (0.45) | OTCDDAH1GSRNOS2NOS1 | |
| SCHEMBL15618245 | 0.87 | OTC (0.51) | OTCDDAH1GSRNOS2NOS1 | |
| SCHEMBL15483719 | 0.86 | OTC (0.50) | OTCDDAH1GSRNOS2NOS1 | |
| SCHEMBL17430453 | 0.85 | CA2 (0.39) | OTCDDAH1CA2CA9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338555-A1 | CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | US | claimed |
| US-20220243210-A1 | ANGIOTENSIN II TYPE 1 RECEPTOR TARGETED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2022-08-04 | — | — | US | claimed |
| WO-2020236755-A2 | ANGIOTENSIN II TYPE 1 RECEPTOR TARGETED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2020-11-26 | — | — | WO | claimed |
| US-20240409672-A1 | MODIFIED ALGINATES AND METHODS OF MAKING AND USING THEREOF | NATIONAL INSTITUTES OF HEALTH | 2024-12-12 | — | — | US | disclosed |
| EP-4422691-A1 | MODIFIED ALGINATES AND METHODS OF MAKING AND USING THEREOF | North Carolina State University (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20230338555-A1 | CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| WO-2023077112-A1 | MODIFIED ALGINATES AND METHODS OF MAKING AND USING THEREOF | NORTH CAROLINA STATE UNIVERSITY (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20220243210-A1 | ANGIOTENSIN II TYPE 1 RECEPTOR TARGETED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2022-08-04 | — | — | US | disclosed |
| WO-2020236755-A2 | ANGIOTENSIN II TYPE 1 RECEPTOR TARGETED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2020-11-26 | — | — | WO | disclosed |
| CN-105026574-B | Cell lines | 米迪缪尼有限公司 | 2019-08-30 | — | — | CN | disclosed |
| CN-104812734-B | Amino acid derivatives | 米迪缪尼有限公司 | 2017-08-22 | — | — | CN | disclosed |
| CN-105026574-A | Cell lines | MEDIMMUNE LLC | 2015-11-04 | — | — | CN | disclosed |
| CN-104812734-A | Amino acid derivatives | ALLOZYNE INC | 2015-07-29 | — | — | CN | disclosed |
| US-8921571-B2 | Pyrrolysine analogs | THE OHIO STATE UNIVERSITY (US) | 2014-12-30 | — | — | US | disclosed |
| US-20130035478-A1 | PYRROLYSINE ANALOGS | THE OHIO STATE UNIVERSITY (US) | 2013-02-07 | — | — | US | disclosed |
| US-8293206-B2 | Achievement of a high therapeutic index through molecular imaging guided targeted drug treatment | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| WO-2011044255-A1 | PYRROLYSINE ANALOGS | THE OHIO STATE UNIVERSITY (US) | 2011-04-14 | — | — | WO | disclosed |
| US-20100074910-A1 | Achievement of a high therapeutic index through molecular imaging guided targeted drug treatment | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| WO-2009148554-A1 | ACHIEVEMENT OF HIGH THERAPEUTIC INDEX THROUGH MOLECULAR IMAGING GUIDED TARGETED DRUG TREATMENT | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338555-A1 | CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | DCLRE1B, RNASE1, LNPEP | OTC 1214/4885DDAH1 2931/4885GSR 2186/4885 |
| US-20130035478-A1 | PYRROLYSINE ANALOGS | UROD, ALDH18A1, HMBS | OTC 437/4885DDAH1 2289/4885GSR 1571/4885 |
| US-20100074910-A1 | Achievement of a high therapeutic index through molecular imaging guided targeted drug treatment | MKI67, CD47, CD68 | OTC 4427/4885DDAH1 2730/4885GSR 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.